Kevin R. Fales

A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models

Tinggui Yin, Marı́a José Lallena, Emiko L. Kreklau et al. · Molecular Cancer Therapeutics · 2014 · 101 citations · Full text

Tumor Biology, Medicine, Malignant Blood Disorder +14

Asymmetric synthesis of cis-(−)-(2R4S)-4-(phosphonomethyl)-2-piperidinecarboxylic acid, a potent NMDA receptor antagonist

Jerry W. Skiles, Peter P. Giannousis, Kevin R. Fales · Bioorganic & Medicinal Chemistry Letters · 1996 · 58 citations

Medicine, Drug Discovery, Asymmetric Synthesis +4

Discovery of <i>N</i>-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3<i>R</i>)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model

Kevin R. Fales, F. George Njoroge, Harold B. Brooks et al. · Journal of Medicinal Chemistry · 2017 · 33 citations · Full text

Pharmacotherapy, Cancer Xenograft Model, Pharmaceutical Chemistry +18

Synthesis of nine-membered carbocycles via sequential higher-order cycloaddition--pinacol rearrangement

James H. Rigby, Kevin R. Fales · Tetrahedron Letters · 1998 · 22 citations

Organic Chemistry, Pinacol Rearrangement, Chemistry +1

Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models

Harold B. Brooks, Timothy I. Meier, Sandaruwan Geeganage et al. · Scientific Reports · 2018 · 20 citations · Full text